Autres langues Claritas Pharmaceuticals, Inc.

Actions

CLAS.H

CA1806342061

Cours en clôture Toronto S.E. Autres places de cotation 00:00:00 19/07/2022			Varia. 5j.	Varia. 1 janv.
0,025 ^CAD	-16,67%		-.--%	-.--%

2021	Claritas met à jour son projet de financement avec Obsidian, reçoit un crédit d'impôt australien et lance la phase 1 de l'étude sur le R-107.	MT
2021	Claritas Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2021	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	18/08/21
Claritas Pharmaceuticals : IIROC Trading Resumption - CLAS	18/08/21
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107	18/08/21
Claritas Pharmaceuticals : IIROC Trading Halt - CLAS	18/08/21
Claritas Announces Grant of Stock Options to Directors and Officers	28/07/21
Claritas Pharmaceuticals : Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	26/07/21
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	26/07/21
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107	21/07/21
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21/07/21
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21/07/21
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23	20/07/21
Claritas Announces Effective Date for Share Consolidation	20/07/21
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) dropped from S&P/TSX Venture Composite Index	19/07/21
Claritas Pharmaceuticals : Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation	11/06/21
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation	10/06/21
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics	01/06/21
Claritas Pharmaceuticals : Announces Settlement of Debt Transaction	31/05/21
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	28/05/21
Claritas Pharmaceuticals Issues Letter to Shareholders	11/05/21
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	30/04/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Claritas Pharmaceuticals, Inc.

Actions

CLAS.H

CA1806342061

Autres langues

Filtres